Inadvertent cardiovascular risk following rofecoxib initiation

Author：

ISSN： 0114-9954

Source： Reactions Weekly, Vol.1, Iss.1067, 2005-01, pp. : 3-3

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Rofecoxib: increased risk of renal and cardiovascular effects

Inpharma, Vol. 1, Iss. 1555, 2006-01 ,pp. : 21-21

Adis International

Access to resources Recommend Favorite

Celecoxib associated with similar cardiovascular risk to rofecoxib

Reactions Weekly, Vol. 1, Iss. 1048, 2005-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Lidocaine: Motor and sensory blockade plus cardiovascular and pulmonary suppression following inadvertent intrathecal administration: case report

Reactions Weekly, Vol. 1, Iss. 1214, 2008-01 ,pp. : 21-22

Adis International

Access to resources Recommend Favorite

Celecoxib and rofecoxib: risk of GI bleeding

Inpharma, Vol. 1, Iss. 1318, 2001-01 ,pp. : 21-21

Adis International

Access to resources Recommend Favorite

Rofecoxib labelling updated following VIGOR results

Inpharma, Vol. 1, Iss. 1335, 2002-01 ,pp. : 21-21

Adis International

Access to resources Recommend Favorite